Alasdair Coles is a neurologist in Cambridge. He was closely involved in the development of alemtuzumab (“Lemtrada”) as a treatment of multiple sclerosis. Since then, he has set up trials of a novel remyelinating drug in multiple sclerosis and of immunotherapy in autoimmune psychosis. He is Chair of the MS Advisory Group of the Association of British Neurologists and chaired the group that drew up the latest NHS England MS Treatment Algorithm.
